Jointown Pharmaceutical Group (600998) Q3 2025 earnings summary

Executive summary

• Achieved strong growth in Q3 2025, with revenue, net profit, and adjusted net profit up 5.41%, 8.46%, and 15.24% year-over-year, respectively.

• Sequentially, Q3 net profit and adjusted net profit rose 11.39% and 16.49% from Q2.

• For the first nine months, revenue and net profit increased 5.20% and 16.46% year-over-year, driven by stable distribution and rapid growth in new business segments.

• Completed a public REITs listing for pharmaceutical logistics infrastructure, contributing RMB 438 million to net profit.

Financial highlights

• Q3 revenue: RMB 38.22 billion; Q3 net profit attributable to shareholders: RMB 529.89 million.

• First nine months revenue: RMB 119.33 billion; net profit attributable to shareholders: RMB 1.98 billion.

• Adjusted net profit for the first nine months: RMB 1.47 billion, down 9.80% year-over-year.

• Basic and diluted EPS for Q3: RMB 0.10; for nine months: RMB 0.39, up 14.71% year-over-year.

• Total assets at Q3-end: RMB 112.28 billion, up 9.65% from year-end 2024.

Outlook and guidance

• Full-year operating cash flow expected to be positive and aligned with business performance.